Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease
- PMID: 16170749
- DOI: 10.1086/466529
Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease
Abstract
The epidemiology of infections with 5 human herpesviruses (HHVs) (HHV-6, HHV-7, HHV-8, varicella zoster virus [VZV], and Epstein-Barr virus [EBV]) was investigated during the first year after solid organ transplantation in 263 patients who received oral ganciclovir or valganciclovir prophylaxis. HHV-6B DNAemia was uncommon, HHV-6A DNAemia was not observed, and HHV-7 DNAemia was prevalent. HHV-6 and HHV-7 DNAemia were not significantly associated with cytomegalovirus (CMV) disease, although a trend toward higher incidence of CMV disease was observed in HHV-6 DNAemic patients. VZV and HHV-8 DNAemia were not detected. EBV infection was common, although incidence of high-level EBV DNAemia was low, especially in patients who received valganciclovir prophylaxis. EBV-related posttransplant lymphoproliferative disease was not observed up to 12 months after transplantation. Compared with historic data, data from the present study suggest that antiviral prophylaxis may lower the incidence, prevalence, or level of DNAemia for infection with HHV-6, HHV-8, VZV, and EBV but not for infection with HHV-7.
Similar articles
-
HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.Transplant Proc. 2005 Mar;37(2):1230-2. doi: 10.1016/j.transproceed.2004.12.004. Transplant Proc. 2005. PMID: 15848678
-
Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients.Transplant Proc. 2010 Jan-Feb;42(1):74-8. doi: 10.1016/j.transproceed.2009.12.032. Transplant Proc. 2010. PMID: 20172284
-
A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.Transplantation. 2006 Mar 27;81(6):856-61. doi: 10.1097/01.tp.0000202724.07714.a2. Transplantation. 2006. PMID: 16570008 Clinical Trial.
-
DNA viruses (CMV, EBV, and the herpesviruses).Semin Respir Crit Care Med. 2011 Aug;32(4):454-70. doi: 10.1055/s-0031-1283285. Epub 2011 Aug 19. Semin Respir Crit Care Med. 2011. PMID: 21858750 Review.
-
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.Am J Clin Dermatol. 2006;7(1):13-29. doi: 10.2165/00128071-200607010-00003. Am J Clin Dermatol. 2006. PMID: 16489840 Review.
Cited by
-
Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.Curr Opin Virol. 2014 Dec;9:53-60. doi: 10.1016/j.coviro.2014.09.006. Epub 2014 Oct 4. Curr Opin Virol. 2014. PMID: 25285614 Free PMC article. Review.
-
Monitoring and managing viral infections in pediatric renal transplant recipients.Pediatr Nephrol. 2012 May;27(5):705-17. doi: 10.1007/s00467-011-1812-2. Epub 2011 Feb 26. Pediatr Nephrol. 2012. PMID: 21359619 Review.
-
Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.Hum Vaccin Immunother. 2017 Dec 2;13(12):2763-2771. doi: 10.1080/21645515.2017.1308988. Epub 2017 May 11. Hum Vaccin Immunother. 2017. PMID: 28494195 Free PMC article.
-
Impact of human herpes virus 6 in liver transplantation.World J Hepatol. 2010 Sep 27;2(9):345-53. doi: 10.4254/wjh.v2.i9.345. World J Hepatol. 2010. PMID: 21161019 Free PMC article.
-
Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients.Transpl Infect Dis. 2011 Feb;13(1):15-23. doi: 10.1111/j.1399-3062.2010.00547.x. Transpl Infect Dis. 2011. PMID: 20636480 Free PMC article.